1.	Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) Phase: Phase III Type: Prevention Status: Completed Age: 20 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 111567, NCT00637195
2.	Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 111507, NCT00652938
3.	Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 26 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: 114590, NCT01277042
4.	Modified Process Hepatitis B Vaccine in Healthy Neonates Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 10 days and under Sponsor: Pharmaceutical / Industry Protocol IDs: 2006_007, V232-056, NCT00322361
5.	Prospective Trial of Vaccine Responses in Childhood Cancer Survivors Phase: Phase II Type: Supportive care Status: Closed Age: 2 to 18 Sponsor: Other Protocol IDs: 07-088, NCT00505063